-
Product Insights
VOC Port Trust Wind Farm
VOC Port Trust Wind Farm is an Onshore Wind project located in Tamil Nadu, India. The project is expected to come online in 2024. Empower your strategies with our VOC Port Trust Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin DR in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifaximin DR in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin DR in Sickle Cell Disease Drug Details: Rifaximin delayed-release...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin Dr in Rosacea
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin DR in Rosacea Drug Details: Rifaximin delayed-release formulation is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sevuparin Sodium in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevuparin Sodium in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sevuparin Sodium in Malaria Drug Details:Sevuparin sodium (DF-02) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crizanlizumab in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Crizanlizumab in Myelofibrosis Drug Details:Crizanlizumab-TMCA (Adakveo, Chylotrez) is a monoclonal antibody, produced by using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crizanlizumab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Crizanlizumab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:Crizanlizumab-TMCA (Adakveo,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crizanlizumab in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Crizanlizumab in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details:Crizanlizumab-TMCA (Adakveo, Chylotrez) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crizanlizumab in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Crizanlizumab in Chronic Kidney Disease (Chronic Renal Failure)Drug Details:Crizanlizumab-TMCA...
-
Company Profile
Munters Group AB – Company Profile
Munters Group AB (Munters) is one of the leading providers of energy efficient air treatment and climate control solutions. It’s solutions include building comfort systems, energy recovery, pollution control and volatile organic compound (VOC) abatement, combined temperature and humidity control, data center cooling, heating, ventilation, cooling, humidification, dehumidification, mass transfer and mist elimination. The company’s product offerings include air intakes and air inlets, coolers and humidifiers, dehumidifiers, combined temperature and humidity control, climate controllers, fans and light traps, heaters, heat...
Add to Basket -
Company Profile
Global Blood Therapeutics Inc – Company Profile
Global Blood Therapeutics Inc (GBT), a subsidiary of Pfizer Inc, is a clinical-stage biopharmaceutical company. The company discovers and develops oxbryta (voxelotor), inclacumab and GBT601. Its products are used for the treatment of various therapeutic areas which includes sickle cell disease (SCD), chronic vaso-occlusive crisis (VOC) prevention, acute VOC re-admission prevention and hemolytic anemia. GBT offers products in tablet form for both children and adults under the brand name Oxbryta. The company also focuses on the development of therapies that...
Add to Basket